Varian's Trilogy products:
This article was originally published in Clinica
Varian Medical Systems has gained US FDA 510(k) market clearance to use its high-energy, "ultra-precise" Trilogy linear accelerators on an expanded range of medical conditions. The clearance also marks the introduction of Varian's new Trilogy Tx image-guided radiosurgery (IGRS) model, designed specifically for surgeons. Physicians can now provide Trilogy treatments for functional lesions such as trigeminal neuralgia and other non-cancerous conditions, said the Palo Alto, California firm. The prior FDA clearance for the Trilogy device was limited to benign and malignant cancers, and arteriovenous malformations.
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Commissioner Hahn’s tweet announcing a return to inspections, while not a new policy, may be signal that FDA understands sponsor concerns with the agency’s limited ability to conduct onsite inspections. Effort may be aimed at reassuring industry even as CRLs related to manufacturing increase.
Rushed final rule seeking to impose draconian cuts on drug reimbursement rates in the Medicare Part B program is certain to face legal and political obstacles. But the data included on international price benchmarks will still have an impact.